Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

Item

http://www.wikidata.org/entity/Q36250758

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

@ast

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

@en

type

Item

label

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

@ast

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

@en

prefLabel

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

@ast

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

@en

P1476

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

@en

P2093

Amar Gajjar

http://www.w3.org/2001/XMLSchema#string

Arzu Onar-Thomas

http://www.w3.org/2001/XMLSchema#string

Brent A Orr

http://www.w3.org/2001/XMLSchema#string

Clinton F Stewart

http://www.w3.org/2001/XMLSchema#string

David C Turner

http://www.w3.org/2001/XMLSchema#string

Karen D Wright

http://www.w3.org/2001/XMLSchema#string

Nidal Boulos

http://www.w3.org/2001/XMLSchema#string

Richard J Gilbertson

http://www.w3.org/2001/XMLSchema#string

Vinay M Daryani

http://www.w3.org/2001/XMLSchema#string

P2860

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

5-fluorouracil: mechanisms of action and clinical strategies

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

DPYD*2A mutation: the most common mutation associated with DPD deficiency.

Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.

C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

Cross-species genomics matches driver mutations and cell compartments to model ependymoma

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.

P304

1620-1627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOV181

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26541630

http://www.w3.org/2001/XMLSchema#string

P932

4633933

http://www.w3.org/2001/XMLSchema#string